{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Methods of Measurement', 'Spiral CT should be performed with cuts of 5 mm or less in slice thickness contiguously.', 'This applies to tumors of the chest and abdomen. A scale should be incorporated into all', 'radiographic measurements. MRI can be performed if required by local law or if CT is', \"contraindicated, and should be documented in the subject's source.\", 'If prior to enrollment, it is known a subject is not able to undergo CT scans with IV', 'contrast due to allergy or renal insufficiency, the decision as to whether a non-contrast CT', 'or MRI should be used to evaluate the subject at baseline and follow-up should be guided', 'by the tumor type under investigation and the anatomic location of the disease. For', 'subjects who develop contraindications to contrast after baseline contrast CT is done, the', 'decision as to whether non-contrast CT or MRI should be made based upon discussion', 'with the AbbVie TA MD.', 'For accurate objective response evaluation, ultrasound (US) should not be used to', 'measure tumor lesions.', 'The utilization of endoscopy and laparoscopy for objective tumor evaluation is not', 'advised. However, such techniques can be useful in confirming complete pathological', 'response when biopsies are obtained.', 'Cytology and histology can be used to differentiate between partial response (PR) and', 'complete response (CR) in rare cases.', 'Baseline Documentation of \"Target\" and \"Non-Target\" Lesions', 'All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total,', 'representative of all involved organs should be identified as target lesions and recorded', 'and measured at baseline. Target lesions should be selected on the basis of their size', '(lesions with the longest diameter), be representative of all involved organs, but in', 'addition should be those that lend themselves to reproducible repeated measurements.', 'Tumor lesions situated in a previously irradiated area, or in an area subjected to other', '132']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'loco-regional therapy, are usually not considered measurable unless there has been', 'demonstrated progression in the lesion.', 'Lymph nodes merit special mention since they are normal anatomical structures which', 'may be visible by imaging even if not involved by tumor. Pathological nodes which are', 'defined as measurable and may be identified as target lesions must meet the criterion of a', 'short axis of > 15 mm by CT scan. Only the short axis of these nodes will contribute to', 'the baseline sum. The short axis of the node is the diameter normally used by radiologists', 'to judge if a node is involved by solid tumor. Nodal size is normally reported as two', 'dimensions in the plane in which the image is obtained (for CT scan this is almost always', 'the axial plane). The smaller of these measures is the short axis. For example, an', 'abdominal node which is reported as being 20 mm X 30 mm has a short axis of 20 mm', 'and qualifies as a malignant, measurable node. In this example, 20 mm should be', 'recorded as the node measurement. All other pathological nodes (those with short axis', '> 10 mm but < 15 mm) should be considered non-target lesions. Nodes that have a short', 'axis < 10 mm are considered non-pathological and should not be recorded or followed.', 'A sum of the longest diameter (LD) for all target lesions will be calculated and reported as', 'the baseline sum LD. If lymph nodes are to be included in the sum, then as noted above,', 'only the short axis is added into the sum. The baseline sum LD will be used as reference', 'by which to characterize the objective tumor response.', 'All other lesions (or sites of disease) including pathological lymph nodes should be', 'identified as non-target lesions and should also be recorded at baseline. Measurements of', 'these lesions are not required, but the presence (stable, increasing or decreasing) or', 'absence of each should be noted throughout follow-up.', 'Evaluation of Target Lesions', 'Complete Response (CR):', 'The disappearance of all target lesions. Any pathological lymph nodes (whether target or', 'non-target) must have reduction in short axis to < 10 mm.', '133']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Partial Response (PR):', 'At least a 30% decrease in the sum of diameters of target lesions, taking as reference the', 'baseline sum diameters.', 'Progressive Disease (PD):', 'At least a 20% increase in the sum of the LD of target lesions, taking as reference the', 'smallest sum LD recorded since the treatment started (baseline or after) or the appearance', 'of one or more new lesions. In addition to the relative increase of 20%, the sum must also', 'demonstrate an absolute increase of at least 5 mm.', 'Stable Disease (SD):', 'Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,', 'taking as reference the smallest sum LD since the treatment started (baseline or after).', 'Assessment of Target Lesions:', 'Lymph nodes identified as target lesions should always have the actual short axis', 'measurement recorded (measured in the same anatomical plane as the baseline', 'examination), even if the nodes regress to below 10 mm on study. This means that when', \"lymph nodes are included as target lesions, the 'sum' of lesions may not be zero even if\", 'complete response criteria are met, since a normal lymph node is defined as having a short', 'axis of < 10 mm. For PR, SD and PD, the actual short axis measurement of the nodes is', 'to be included in the sum of target lesions.', 'All lesions (nodal and non-nodal) recorded at baseline should have their actual', 'measurements recorded at each subsequent evaluation, even when very small (<< mm).', 'However, sometimes target lesions or lymph nodes become too small to measure. If it is', 'in the opinion of the radiologist that the lesion has likely disappeared, the measurement', 'should be recorded as 0 mm. If the lesion is believed to be present, but too small to', 'measure, a default value of 5 mm should be assigned (as derived from the 5 mm CT slice', '134']\n\n###\n\n", "completion": "END"}